Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2017-09-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of dalantercept plus
sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the
recommended dose level of dalantercept in combination with sorafenib.